Department of Dermatology, Oregon Health and Science University, Portland, Oregon.
National Expertise Center for Atopic Dermatitis, Department of Dermatology and Allergology, University Medical Center Utrecht, Utrecht, The Netherlands.
J Am Acad Dermatol. 2017 Oct;77(4):623-633. doi: 10.1016/j.jaad.2017.06.042. Epub 2017 Aug 10.
Although most patients with atopic dermatitis (AD) are effectively managed with topical medication, a significant minority require systemic therapy. Guidelines for decision making about advancement to systemic therapy are lacking.
To guide those considering use of systemic therapy in AD and provide a framework for evaluation before making this therapeutic decision with the patient.
A subgroup of the International Eczema Council determined aspects to consider before prescribing systemic therapy. Topics were assigned to expert reviewers who performed a topic-specific literature review, referred to guidelines when available, and provided interpretation and expert opinion.
We recommend a systematic and holistic approach to assess patients with severe signs and symptoms of AD and impact on quality of life before systemic therapy. Steps taken before commencing systemic therapy include considering alternate or concomitant diagnoses, avoiding trigger factors, optimizing topical therapy, ensuring adequate patient/caregiver education, treating coexistent infection, assessing the impact on quality of life, and considering phototherapy.
Our work is a consensus statement, not a systematic review.
The decision to start systemic medication should include assessment of severity and quality of life while considering the individual's general health status, psychologic needs, and personal attitudes toward systemic therapies.
尽管大多数特应性皮炎(AD)患者通过局部药物治疗即可得到有效管理,但仍有相当一部分患者需要接受系统治疗。目前缺乏关于推进系统治疗决策的指南。
为考虑使用 AD 系统治疗的患者提供指导,并在与患者做出这一治疗决策之前,为评估提供框架。
国际特应性皮炎理事会的一个小组确定了在开具全身治疗药物之前需要考虑的方面。将主题分配给专家评审员,由他们进行特定主题的文献回顾,参考现有指南,并提供解释和专家意见。
我们建议在开始全身治疗之前,采用系统和整体的方法来评估患有严重 AD 体征和症状以及对生活质量有影响的患者。在开始全身治疗之前采取的措施包括考虑其他或同时存在的诊断、避免触发因素、优化局部治疗、确保患者/照顾者得到充分教育、治疗并存的感染、评估对生活质量的影响以及考虑光疗。
我们的工作是一项共识声明,而非系统评价。
开始全身药物治疗的决定应包括评估严重程度和生活质量,同时考虑个体的整体健康状况、心理需求以及对全身治疗的个人态度。